Herman Schreuder

Fragment deconstruction of small, potent factor Xa inhibitors: exploring the superadditivity energetics of fragment linking in protein-ligand complexes.

Hans Matter, Armin Bauer, Marc Nazaré, 2012, Angewandte Chemie.

Probing the subpockets of factor Xa reveals two binding modes for inhibitors based on a 2-carboxyindole scaffold: a study combining structure-activity relationship and X-ray crystallography.

Hans Matter, Volker Laux, Armin Bauer, 2005, Journal of medicinal chemistry.

A new cytokine-receptor binding mode revealed by the crystal structure of the IL-1 receptor with an antagonist

Ronald W. Barrett, R. Barrett, H. Schreuder, 1997, Nature.

Evidence for C-Cl/C-Br...pi interactions as an important contribution to protein-ligand binding affinity.

Stefan Güssregen, Hans Matter, Armin Bauer, 2009, Angewandte Chemie.

Structural requirements for factor Xa inhibition by 3-oxybenzamides with neutral P1 substituents: combining X-ray crystallography, 3D-QSAR, and tailored scoring functions.

Hans Matter, Volker Laux, Marc Nazaré, 2005, Journal of medicinal chemistry.

Design and quantitative structure-activity relationship of 3-amidinobenzyl-1H-indole-2-carboxamides as potent, nonchiral, and selective inhibitors of blood coagulation factor Xa.

Hans Matter, Fahad Al-Obeidi, Armin Walser, 2002, Journal of medicinal chemistry.

5-Chlorothiophene-2-carboxylic acid [(S)-2-[2-methyl-3-(2-oxopyrrolidin-1-yl)benzenesulfonylamino]-3-(4-methylpiperazin-1-yl)-3-oxopropyl]amide (SAR107375), a selective and potent orally active dual thrombin and factor Xa inhibitor.

Peter Florian, Markus Follmann, Frederic Petit, 2013, Journal of medicinal chemistry.